Donepezil Double Blind Trial for ECT Memory Disfunction

B

BeerYaakov Mental Health Center

Status and phase

Unknown
Phase 4

Conditions

Schizophreniform Disorder
Schizophrenia
Schizoaffective Disorder

Treatments

Drug: Donepezil

Study type

Interventional

Funder types

Other

Identifiers

NCT00465283
Donepezil-180CTIL

Details and patient eligibility

About

This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT. Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical Interview for DSM-IV (SCID)

Exclusion criteria

  • History of serious neurological disorders including neurodegenerative deseases, mental retardation, substance and/or alcohol dependence.
  • Pregnant women
  • Patients who recieved ECT within 6 month
  • Patients whith contraindication to Donepezil treatment.
  • Patients with Lithium treatment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

40 participants in 2 patient groups, including a placebo group

Donepezil
Active Comparator group
Treatment:
Drug: Donepezil
placebo
Placebo Comparator group
Treatment:
Drug: Donepezil

Trial contacts and locations

0

Loading...

Central trial contact

Marina Kupchik, MD; Tali Nachshoni, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems